EQ-5D-5L user guide, version 3.0, September 2019
GLP-1 receptor agonists should only be continued if there is an adequate response, defined as a reduction of at least 11 mmol/mol (1.0%) in HbA1c and a weight loss of at least 3% of initial body weight at six months
Semaglutide is shown to be a superior weight loss agent in comparison to other GLP-1-RA drugs, such as liraglutide
The GLP-1 component helps reduce appetite and cravings, while the GIP component is thought to improve how the body breaks down sugar and fat
This drives provider confidence and accelerates adoption
DOI: 10.1056/NEJMoa2413258 [Google Scholar] Hawary OA, Wadie W, El-Said YAM, Hassan OF